Third Harmonic Bio Appoints Christopher Murphy as Chief Financial and Business Officer and Provides Business Update
04 Januar 2024 - 2:00PM
Third Harmonic Bio, Inc. (Nasdaq: THRD), a biopharmaceutical
company focused on advancing the next wave of medicine for
inflammatory diseases, today announced the appointment of
Christopher Murphy as Chief Financial and Business Officer. Chris
brings extensive experience in business development, commercial
operations, corporate strategy and investment banking in the
biopharmaceutical industry to the company’s leadership team. In his
role, Chris will be responsible for strategic leadership and
direction of the company’s finance, corporate strategy, and
business development functions.
“We are very excited to welcome Chris, a high-caliber enterprise
leader with a clear track record of translating thoughtful
corporate strategy into meaningful shareholder value,” said Natalie
Holles, Chief Executive Officer at Third Harmonic Bio. “I look
forward to Chris’ thought partnership as we advance THB335 for the
treatment of mast-cell mediated inflammatory diseases and evaluate
opportunities to expand our work through strategic business
development opportunities.”
Chris Murphy most recently served as a member of the leadership
team that transformed Horizon Therapeutics PLC from a primary
care-focused specialty pharmaceutical company with a market
capitalization of approximately $800 million to a fully integrated,
highly profitable rare disease-focused biopharmaceutical company,
which was acquired by Amgen Inc. for $28 billion in October 2023.
While at Horizon, he served in roles of increasing responsibility
in business development and commercial operations. In business
development, Chris was most recently Group Vice President, where he
oversaw a number of strategic transactions and integrations. In
commercial operations, Chris most recently served as Group Vice
President, overseeing market access, sales and marketing
operations, and analytics across Horizon’s portfolio of medicines,
including during the preparation and initial launch of TEPEZZA®
(teprotumumab-trbw) for the treatment of thyroid eye disease.
Earlier in his career, Chris held positions of increasing
responsibility in the Life Sciences Investment Banking Group at JMP
Securities LLC.
Third Harmonic Bio also provided a business update on its lead
program, THB335, a potent, highly selective oral small molecule KIT
inhibitor in development for the treatment of chronic spontaneous
urticaria and other mast-cell mediated inflammatory disorders.
IND-enabling toxicology studies of THB335 are nearing completion,
and the company recently completed its pre-IND written
correspondence with the U.S. FDA. The company is on track to file a
U.S. IND and initiate a Phase 1 SAD/14-day MAD study of THB335
during the first half of 2024.
The company maintains a strong financial position with cash and
cash equivalents totaling $273.9 million as of September 30,
2023.
About Third Harmonic Bio, Inc. Third
Harmonic Bio is a biopharmaceutical company focused on advancing
the next wave of medicine for inflammatory diseases through the
development of novel highly selective, small-molecule inhibitors of
KIT, a cell surface receptor that serves as the master regulator of
mast cell function and survival. Early clinical studies demonstrate
that KIT inhibition has the potential to revolutionize the
treatment of a broad range of mast-cell-mediated inflammatory
diseases, and that a titratable, oral, intracellular small molecule
inhibitor may provide the optimal therapeutic profile against this
target. Third Harmonic Bio’s lead product candidate, THB335, is a
titratable, oral, intracellular small molecule inhibitor expected
to enter clinical trials during the first half of 2024. For more
information, please visit the Third Harmonic Bio website:
www.thirdharmonicbio.com.
Forward-Looking Statements This press
release contains “forward-looking” statements within the meaning of
the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995, including, but not limited to, the
roles and responsibilities of Chris Murphy, the timing of Third
Harmonic Bio completing IND-enabling studies of THB335, the filing
a U.S. IND application for THB335, and the expected timing for
clinical activities. Forward-looking statements can be identified
by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,”
“believe,” “project,” “estimate,” “expect,” “strategy,” “future,”
“likely,” “may,” “should,” “will” and similar references to future
periods. These statements are subject to numerous risks and
uncertainties, including risks and uncertainties related to Third
Harmonic Bio’s cash forecasts, ability to advance its product
candidates, the receipt and timing of potential regulatory
submissions, designations, approvals and commercialization of
product candidates, our ability to protect our intellectual
property, the timing and results of preclinical and clinical
trials, changes to laws or regulations, market conditions,
geopolitical events, and further impacts of pandemics or health
epidemics, that could cause actual results to differ materially
from what Third Harmonic Bio expects. Further information on
potential risk factors that could affect Third Harmonic Bio’s
business and its financial results are detailed under the heading
“Risk Factors” included in Third Harmonic Bio’s Quarterly Report on
Form 10-Q for the nine months ended September 30, 2023, filed with
the U.S. Securities and Exchange Commission (“SEC”) on November 9,
2023, and in Third Harmonic Bio’s other filings filed from time to
time with the SEC. Third Harmonic Bio undertakes no obligation to
publicly update any forward-looking statement, whether written or
oral, that may be made from time to time, whether as a result of
new information, future developments or otherwise.
TEPEZZA® is a registered trademark of Amgen
Inc. Investor & Media
Contact: Lori
Murray lori.murray@thirdharmonicbio.com
Third Harmonic Bio (NASDAQ:THRD)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Third Harmonic Bio (NASDAQ:THRD)
Historical Stock Chart
Von Mai 2023 bis Mai 2024